Eisai Announces Filing for Marketing Authorization of BELVIQ® (lorcaserin HCI)
for Chronic Weight Management in Brazil
WOODCLIFF LAKE, N.J., Feb. 12, 2014
WOODCLIFF LAKE, N.J., Feb. 12, 2014 /PRNewswire/ --Eisai Inc. announced today
that its subsidiary Eisai Laboratorios Ltda has filed for the marketing
authorization of BELVIQ as a treatment for chronic weight management with the
Brazilian Health Surveillance Agency (Anvisa).
"In keeping with Eisai's human health care mission we are committed to
providing access to innovative therapies to patients and physicians
worldwide," said Frank Ciriello, Senior Vice President, Eisai Inc. "According
to recent estimates, approximately 65 percent of the adult population in
Brazil is overweight or obese, making this country an important priority for
BELVIQ is being submitted for marketing authorization in Brazil as an adjunct
to a reduced-calorie diet and increased physical activity for chronic weight
management in adult obese patients (initial body mass index, or BMI, ≥ 30
kg/m^2), or overweight patients (initial BMI ≥ 27 kg/m^2) in the presence of
at least one weight-related comorbid condition (e.g., hypertension,
dyslipidemia, cardiovascular disease, type 2 diabetes managed with oral
hypoglycemic agents, or sleep apnea).
Under its agreement with Arena Pharmaceuticals, Eisai is responsible for
seeking the regulatory approval and subsequent marketing and distribution of
BELVIQ in Brazil. Arena has granted Eisai marketing and distribution rights to
BELVIQ for all countries worldwide, except South Korea, Taiwan, Australia, New
Zealand and Israel.
BELVIQ is used along with a reduced-calorie diet and increased physical
activity for chronic weight management in adults who have a body mass index
(BMI) of 30 kg/m^2 or greater (obese), or BMI of 27 kg/m^2 or greater
(overweight) with at least one weight-related medical condition such as high
blood pressure, high cholesterol, or type 2 diabetes. It is not known if
BELVIQ is safe and effective when taken with other prescription,
over-the-counter, or herbal weight loss products, nor is it known if BELVIQ
changes the risk of heart problems or stroke, or death due to heart problems
BELVIQ is believed to decrease food consumption and promote satiety by
selectively activating serotonin 2C receptors in the brain. The exact
mechanism of action of BELVIQ is not known.
Important Safety Information
oPregnancy: Do not take BELVIQ if you are pregnant or planning to become
pregnant, as weight loss offers no potential benefit during pregnancy and
BELVIQ may harm your unborn baby.
oSerotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions:
Before using BELVIQ, tell your doctor about all the medicines you take,
especially medicines that treat depression, migraines, mental problems, or
the common cold. These medicines may cause serious or life-threatening
side effects if taken with BELVIQ. Call your doctor right away if you
experience agitation, hallucinations, confusion, or other changes in
mental status; coordination problems; uncontrolled muscle spasms; muscle
twitching; restlessness; racing or fast heartbeat; high or low blood
pressure; sweating; fever; nausea; vomiting; diarrhea; or stiff muscles.
oValvular heart disease: Some people taking medicines like BELVIQ have had
heart valve problems. Call your doctor right away if you experience
trouble breathing; swelling of the arms, legs, ankles, or feet; dizziness,
fatigue, or weakness that will not go away; or fast or irregular
heartbeat. Before taking BELVIQ, tell your doctor if you have or have had
oChanges in attention or memory: BELVIQ may slow your thinking. You should
not drive a car or operate heavy equipment until you know how BELVIQ
oMental problems: Taking too much BELVIQ may cause hallucinations, a
feeling of being high or in a very good mood, or feelings of standing
outside your body.
oDepression or thoughts of suicide: Call your doctor right away if you
notice any mental changes, especially sudden changes in your mood,
behaviors, thoughts, or feelings, or if you have depression or thoughts of
oLow blood sugar: Weight loss can cause low blood sugar in people taking
medicines for type 2 diabetes, such as insulin or sulfonylureas. Blood
sugar levels should be checked before and while taking BELVIQ. Changes to
diabetes medication may be needed if low blood sugar develops.
oPainful erections: If you have an erection lasting more than 4 hours while
on BELVIQ, stop taking BELVIQ and call your doctor or go to the nearest
emergency room right away.
oSlow heartbeat: BELVIQ may cause your heart to beat slower.
oDecreases in blood cell count: BELVIQ may cause your red and white blood
cell counts to decrease.
oIncrease in prolactin: BELVIQ may increase the amount of a hormone called
prolactin. Tell your doctor if your breasts begin to make milk or a milky
fluid, or if you are a male and your breasts increase in size.
oMost common side effects in patients without diabetes: Headache,
dizziness, fatigue, nausea, dry mouth, and constipation.
oMost common side effects in patients with diabetes: Low blood sugar,
headache, back pain, cough, and fatigue.
oNursing: BELVIQ should not be taken while breastfeeding.
oDrug interactions: Before taking BELVIQ, tell your doctor if you take
medicines for depression, migraines, or other medical conditions, such as:
triptans; medicines used to treat mood, anxiety, psychotic or thought
disorders, including tricyclics, lithium, selective serotonin reuptake
inhibitors, selective serotonin-norepinephrine reuptake inhibitors,
monoamine oxidase inhibitors, or antipsychotics; cabergoline; linezolid
(an antibiotic); tramadol; dextromethorphan (an over-the-counter (OTC)
common cold/cough medicine); OTC supplements such as tryptophan or St.
John's Wort; or erectile dysfunction medicines.
BELVIQ is a federally controlled substance (CIV) because it may be abused or
lead to drug dependence.
For more information about BELVIQ, click here for the full Product Information
or visit www.BELVIQ.com.
BELVIQ^® is a registered trademark of Arena Pharmaceuticals GmbH.
About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., we have a passionate commitment to patient care that is the driving
force behind our efforts to help address unmet medical needs. We are a fully
integrated pharmaceutical business with discovery, clinical, manufacturing and
marketing capabilities. Our key areas of commercial focus include oncology and
specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To
learn more about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based
Media Inquiries Investor Inquiries
Laurie Landau Alex Scott
Eisai Inc. Eisai Inc.
(201) 746-2510 (201) 746-2177
SOURCE Eisai Inc.
Press spacebar to pause and continue. Press esc to stop.